Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04172194

Enrollment

Registered

2019-11-21

Start date

2009-01-01

Completion date

2014-12-31

Last updated

2019-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Hepatocellular

Brief summary

Background: The association of transcatheter arterial chemotherapy infusion (TAC) with percutaneous ablation (PT) has been introduced as a method to increase the ablative zone. The aim of this study was to evaluate the efficacy of PT and TAC performed in a single session for HCCs between 30 and 50 mm or oligonodular up to 30 mm. Methods: Thirty patients with a histologically proven HCC, uninodular between 30 and 50 mm or oligonodular (n≤3) up to 30 mm, treatment-naïve and non-metastatic, received combination treatment (PT+TAC group). A control group consisted of 34 patients with uninodular HCC up to 30 mm without any poor prognostic criteria treated with PT alone (PT group).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

\- hepatocellular carcinoma pouved by pathology,

Exclusion criteria

\- metastases

Design outcomes

Primary

Measure	Time frame	Description
overall survival	30 minutes	death

Secondary

Measure	Time frame	Description
relapse free survival	30 minutes	relapse
tolerance	30 minutes	apparition of complication define by CTCAE v5.0

Countries

France

Outcome results